---
title: "Cobenfy (xanomeline and trospium chloride) in schizophrenia: Clinical trials questions"
description: "Clinical trials questions on Cobenfy (xanomeline and trospium chloride) in schizophrenia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How effective was COBENFY for schizophrenia in clinical trials? How were the 5-week COBENFY EMERGENT trials designed? What were the long-term COBENFY trials (EMERGENT-4 and EMERGENT-5)? What was COBENFY adherence in the 52-week EMERGENT-5 outpatient trial? 4 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/cobenfy--schizophrenia/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Cobenfy (xanomeline and trospium chloride) in schizophrenia: Clinical trials questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Cobenfy](https://packageinserts.bms.com/pi/pi_cobenfy.pdf)

## Study results

<a id="cobenfy-pivotal-efficacy"></a>

### How effective was COBENFY for schizophrenia in clinical trials?

> “EMERGENT-1 was a phase 2 trial, and EMERGENT-2 & -3 were phase 3 trials. EMERGENT-2 & -3 showed a statistically significant reduction from baseline to Week 5 in the PANSS Total Score compared with the placebo group.<sup>1,2,4</sup>”

Source: [COBENFY: Efficacy Data of COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/efficacy#:~:text=EMERGENT%2D1%20was%20a%20phase%202,Score%20compared%20with%20the%20placebo)

> “In Study 1 and Study 2, patients randomized to COBENFY showed a statistically significant 
> reduction from baseline to Week 5 in the PANSS Total Score compared to the placebo group. 
> The results of Studies 1 and 2 are shown in Table 4. A secondary endpoint, the change from 
> baseline to Week 5 on the Clinical Global Impression–Severity (CGI-S) score, was statistically 
> significant for COBENFY compared to placebo in Study 1. The CGI-S is a validated clinician-rated 
> scale that measures the patient’s current illness state and overall clinical state on a 1 (normal, 
> not at all ill) to 7-point (extremely ill) scale.
> Examination of subgroups by age, sex, and race did not suggest differences in response in the 
> study (there were no patients over 65 years of age).
> Table 4:	
> Primary Efficacy Results for Change from Baseline in PANSS Total Score 
> at Week 5 in Adults with Schizophrenia (Studies 1 and 2)
> Primary Efficacy Endpoint: PANSS Total Score
> Study 
> Number
> Treatment 
> Group
> N
> Mean Baseline 
> Score (SD)
> LS Mean 
> Change from 
> Baseline (SE)
> Placebo-subtracted 
> Difference 
> (95% CI) <sup>a</sup> 
> 1
> COBENFY
> 117
> 98.2 (8.9)
> -21.2 (1.7)
> -9.6 (-13.9, -5.2)*
> Placebo
> 119
> 97.7 (9.4)
> -11.6 (1.6)
> 2
> COBENFY
> 114
> 96.9 (8.8)
> -20.6 (1.6)
> -8.4 (-12.4, -4.3)*
> Placebo
> 120
> 96.5 (8.8)
> -12.2 (1.6)
> The PANSS Total Score may range from 30 to 210; higher scores reflect greater symptom severity.
> SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval.
> a	  Difference (drug minus placebo) in LS mean change from baseline.
> * Statistically significantly superior to placebo.”

Source: [COBENFY: Prescribing information, page 7, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=7)

Note: The prescribing information identifies the two placebo-controlled trials as Study 1 (NCT04659161) and Study 2 (NCT04738123).

## Clinical trials

<a id="cobenfy-short-trial-population"></a>

### How were the 5-week COBENFY EMERGENT trials designed?

> “Three 5-week studies* evaluated mean change in PANSS total score in adult patients with schizophrenia experiencing acute psychosis.<sup>6†</sup>
>
> Primary end point<sup>6</sup>:
>
> Change in PANSS total score from baseline at Week 5
>
> Prespecified secondary end points<sup>1-3</sup>:
>
> Change from baseline at Week 5 in PANSS positive subscale score, PANSS negative subscale score, PANSS Marder negative factor score, and CGI-S score
> Proportion of participants with at least a 30% reduction from baseline to Week 5 in PANSS total score (EMERGENT-2 & -3 only)
> *	Pivotal 5-week trials were placebo controlled.<sup>3,9</sup>
> <sup>†</sup>	Patients who were newly diagnosed or were experiencing their first treated episode of schizophrenia were excluded.<sup>1,6,7,10</sup>”

Source: [COBENFY: COBENFY™ (xanomeline and trospium chloride) Clinical Trials | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/efficacy/clinical-trials#:~:text=Three%205%2Dweek%20studies%2A%20evaluated%20mean,treated%20episode%20of%20schizophrenia%20were)

<a id="cobenfy-long-term-program"></a>

### What were the long-term COBENFY trials (EMERGENT-4 and EMERGENT-5)?

> “Two 52-week open-label studies evaluated long-term safety and efficacy<sup>4,5</sup>
> Two long-term, 52-week, phase 3, open-label studies<sup>4,5,7</sup>
> EMERGENT-4 included patients who previously completed the treatment period of EMERGENT-2 or EMERGENT-3<sup>4</sup>
> EMERGENT-5 included a patient population with the following select characteristics<sup>7</sup>:
> Aged 18 to 65 years at time of screening
> No psychiatric hospitalization, acute crisis intervention, or other inpatient care within 8 weeks prior to screening
> PANSS score of ≤80
> CGI-S score of ≤4
> Received an oral antipsychotic medication within 30 days prior to screening
> Antipsychotic down-taper, if clinically appropriate in the opinion of the investigator, may occur during the screening phase
> The primary objective of these studies was to assess the long-term safety and tolerability of COBENFY<sup>4,5</sup>
> The secondary objective was to assess the long-term efficacy and evaluate plasma concentrations of xanomeline and trospium chloride after administration of COBENFY<sup>7</sup>
> Patients with a history of treatment resistance to antipsychotic medications were excluded from these trials<sup>6,7,¶</sup>
> <sup>¶</sup>	Failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the past 12 months or having received clozapine within the past year (for EMERGENT-4) or 3 years (for EMERGENT-5).<sup>7</sup>”

Source: [COBENFY: COBENFY™ (xanomeline and trospium chloride) Clinical Trials | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/efficacy/clinical-trials#:~:text=Two%2052%2Dweek%20open%2Dlabel%20studies%20evaluated,EMERGENT%2D4%29%20or%203%20years%20%28for)

<a id="cobenfy-outpatient-trial-adherence"></a>

### What was COBENFY adherence in the 52-week EMERGENT-5 outpatient trial?

> “On average, patients took 97% of their COBENFY twice-daily doses for the duration of their enrollment in EMERGENT-5, a 52-week, long-term, outpatient study*
>
> *	This represents patients who took at least 1 dose of COBENFY in the EMERGENT-5 clinical study. 566 patients were enrolled in EMERGENT-5, and 277 completed the 52-week outpatient trial. Patients included in this analysis may not have completed the 52-week outpatient trial. Adherence was ensured by study site personnel (during in-clinic visits) and by a digital adherence tool. Treatment adherence was calculated as number of doses taken compared to the number planned.<sup>12,14</sup>”

Source: [COBENFY: Dosing COBENFY™ (xanomeline and trospium chloride) | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/dosing#:~:text=On%20average%2C%20patients%20took%2097%25,taken%20compared%20to%20the%20number)

## Related pages
- [Medical information: Cobenfy (xanomeline and trospium chloride): Schizophrenia](https://www.evicenter.com/medical-information/cobenfy--schizophrenia)
- [Indication](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/safety)
- [Specific populations](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/access-and-coverage)
